Summary of Significant Accounting Policies and Estimates (Tables)
|
12 Months Ended |
Dec. 31, 2016 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of Accumulated Other Comprehensive Income (Loss) |
The change in accumulated other comprehensive income (loss) presented on the consolidated balance sheets for the year ended December 31, 2016, is reflected in the table below net of tax: | | | Foreign | | | | | Currency | | | | | Translation | | | Balance at December 31, 2015 | | $ | (1) | | | Other comprehensive loss before reclassification | | | 80 | | | Amounts reclassified from accumulated other comprehensive income (loss) | | | - | | | Net current period other comprehensive income | | | 80 | | | Balance at December 31, 2016 | | $ | 79 |
|
|
| Schedule of Customer Deposits, Advances, Deferred Revenues, and Deferred Unit Costs |
Deferred revenues and deferred cost of revenues consisted of the following:
| | | December 31, | | | | | 2016 | | 2015 | | | Customer deposits and advances | | $ | 47 | | $ | 48 | | | Deferred medical device revenues | | | - | | | 7,388 | | | Deferred rental income | | | 60 | | | 71 | | | Deferred extended maintenance and support | | | 1,523 | | | 1,066 | | | Total deferred revenues | | | 1,630 | | | 8,573 | | | Less current portion | | | (825) | | | (3,960) | | | Deferred revenues, non-current | | $ | 805 | | $ | 4,613 | | | | | | | | | | | | Deferred medical device unit costs | | $ | - | | $ | 4,590 | | | Less current portion | | | - | | | (2,088) | | | Deferred cost of revenue, non-current | | $ | - | | $ | 2,502 | |
|
| Schedule of basic and diluted net income (loss) per share |
Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of common stock, adjusted to include conversion of certain stock options and warrants for common stock during the period, as follows: | | | Years ended December 31, | | | | | 2016(1)
| | | 2015 | | | 2014 | | | Numerator: | | | | | | | | | | | | | | | | | | | | | | | | | | | | Net loss applicable to common stockholders | | $ | (33,815) | | | $ | (24,245) | | | $ | (33,769) | | | Adjustment for gain on fair value of warrant liability | | | (4,286) | | | | (2,505) | | | | - | | | Adjusted net loss used for dilution calculation | | $ | (38,101) | | | $ | (26,750) | | | $ | (33,769) | | | | | | | | | | | | | | | | | Denominator | | | | | | | | | | | | | | Weighted-average number of shares outstanding | | | 18,126 | | | | 14,606 | | | | 11,181 | | | Effect of potential dilutive shares | | | 496 | | | | 3 | | | | - | | | Dilutive weighted-average number of shares outstanding | | | 18,622 | | | | 14,609 | | | | 11,181 | | | | | | | | | | | | | | | | | Net loss per share applicable to common stockholders | | | | | | | | | | | | | | Basic | | $ | (1.87) | | | $ | (1.66) | | | $ | (3.02) | | | Diluted | | $ | (2.05) | | | $ | (1.83) | | | $ | (3.02) | | | (1) | Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition). |
|
| Schedule of Antidilutive Securities |
The following potential dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive: | | | Years ended December 31, | | | | | 2016 | | | 2015 | | | 2014 | | | Options to purchase common stock | | | 2,477 | | | | 1,963 | | | | 1,542 | | | Warrants for common stock | | | 1,963 | | | | 1,963 | | | | 1,971 | | | Common stock issuable upon conversion of preferred shares | | | - | | | | 1,876 | | | | - | | | Total common stock equivalents | | | 4,440 | | | | 5,802 | | | | 3,513 | |
|